{"filing":{"accession_number":"0001193125-26-269557","cik":"0000876343","ticker":"LCTX","company_name":"Lineage Cell Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"lctx-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/lctx-20260610.htm"},"events":[{"id":10297,"run_id":9032,"accession_number":"0001193125-26-269557","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Lineage Cell Therapeutics held its annual meeting of shareholders on June 10, 2026, with voting results disclosed for three matters: election of seven directors, ratification of Baker Tilly US, LLP as independent auditor, and advisory approval of named executive officer compensation. Detailed vote tallies including votes for, against, withheld, abstentions, and broker non-votes are provided for each matter.","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6583,"accession_number":"0001193125-26-269557","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Company's annual meeting held on June 10, 2026, covering three matters: election of seven directors, ratification of the independent auditor (Baker Tilly US, LLP), and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:39.048712+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10298,"run_id":9032,"accession_number":"0001193125-26-269557","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"summary":"The Company withdrew its CIRM Grant application for OPC1 clinical development following comments from CIRM, though the withdrawal does not impact the Company's current and planned development of OPC1 in the ongoing DOSED clinical study.","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6584,"accession_number":"0001193125-26-269557","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The Company withdrew its CIRM Grant application for OPC1 clinical development following comments from CIRM. While the withdrawal itself is disclosed, the filing explicitly states it \"does not impact the Company's current and planned development of OPC1\" in the ongoing DOSED clinical study. This is a routine administrative action regarding a funding application rather than a material event affecting the registrant's financial condition or development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:39.048712+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6583,"accession_number":"0001193125-26-269557","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Company's annual meeting held on June 10, 2026, covering three matters: election of seven directors, ratification of the independent auditor (Baker Tilly US, LLP), and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:39.048712+00:00","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-06-12"},{"id":6584,"accession_number":"0001193125-26-269557","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The Company withdrew its CIRM Grant application for OPC1 clinical development following comments from CIRM. While the withdrawal itself is disclosed, the filing explicitly states it \"does not impact the Company's current and planned development of OPC1\" in the ongoing DOSED clinical study. This is a routine administrative action regarding a funding application rather than a material event affecting the registrant's financial condition or development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:39.048712+00:00","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-06-12"}]}